Richardson P - Search Results

1

Pomalidomide-bortezomib-dexamethasone in relapsed or refractory multiple myeloma: Japanese subset analysis of OPTIMISMM.

Sunami K, Matsue K, Suzuki K, Takezako N, Shinagawa A, Sakurai S, Tamakoshi H, Biyukov T, Peluso T, Richardson P. Sunami K, et al. Among authors: richardson p. Cancer Sci. 2020 Jun;111(6):2116-2122. doi: 10.1111/cas.14415. Epub 2020 May 13. Cancer Sci. 2020. PMID: 32297407 Free PMC article. Clinical Trial.

2

Neutropenic enterocolitis as a complication of high dose chemotherapy with stem cell rescue in patients with solid tumors: a case series with a review of the literature.

Avigan D, Richardson P, Elias A, Demetri G, Shapiro M, Schnipper L, Wheeler C. Avigan D, et al. Among authors: richardson p. Cancer. 1998 Aug 1;83(3):409-14. Cancer. 1998. PMID: 9690531

3

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC. Hideshima T, et al. Among authors: richardson p. Cancer Res. 2001 Apr 1;61(7):3071-6. Cancer Res. 2001. PMID: 11306489

4

Thalidomide in multiple myeloma.

Richardson P, Hideshima T, Anderson K. Richardson P, et al. Biomed Pharmacother. 2002 May;56(3):115-28. doi: 10.1016/s0753-3322(02)00168-3. Biomed Pharmacother. 2002. PMID: 12046682 Review.

5

Novel strategies in the treatment of relapsed/refractory multiple myeloma. From the Multiple Myeloma Research Foundation.

Richardson P. Richardson P. Oncology (Williston Park). 2003 Aug;17(8):1063-5. Oncology (Williston Park). 2003. PMID: 12966673 No abstract available.

6

Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells.

Chauhan D, Li G, Podar K, Hideshima T, Mitsiades C, Schlossman R, Munshi N, Richardson P, Cotter FE, Anderson KC. Chauhan D, et al. Among authors: richardson p. Blood. 2004 Oct 15;104(8):2458-66. doi: 10.1182/blood-2004-02-0547. Epub 2004 Jun 24. Blood. 2004. PMID: 15217830 Free article.

7

Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity.

Richardson P, Schlossman R, Jagannath S, Alsina M, Desikan R, Blood E, Weller E, Mitsiades C, Hideshima T, Davies F, Doss D, Freeman A, Bosch J, Patin J, Knight R, Zeldis J, Dalton W, Anderson K. Richardson P, et al. Mayo Clin Proc. 2004 Jul;79(7):875-82. doi: 10.4065/79.7.875. Mayo Clin Proc. 2004. PMID: 15244383 Clinical Trial.

8

Proteasome inhibitor therapy in multiple myeloma.

Chauhan D, Hideshima T, Mitsiades C, Richardson P, Anderson KC. Chauhan D, et al. Among authors: richardson p. Mol Cancer Ther. 2005 Apr;4(4):686-92. doi: 10.1158/1535-7163.MCT-04-0338. Mol Cancer Ther. 2005. PMID: 15827343 Review.

9

Identification and validation of novel therapeutic targets for multiple myeloma.

Hideshima T, Chauhan D, Richardson P, Anderson KC. Hideshima T, et al. Among authors: richardson p. J Clin Oncol. 2005 Sep 10;23(26):6345-50. doi: 10.1200/JCO.2005.05.024. J Clin Oncol. 2005. PMID: 16155018 Review.

10

A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.

Chauhan D, Li G, Podar K, Hideshima T, Neri P, He D, Mitsiades N, Richardson P, Chang Y, Schindler J, Carver B, Anderson KC. Chauhan D, et al. Among authors: richardson p. Cancer Res. 2005 Sep 15;65(18):8350-8. doi: 10.1158/0008-5472.CAN-05-0163. Cancer Res. 2005. PMID: 16166312

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,365 results

Search Page